Heart failure with preserved ejection fraction: present status and future directions

다국어 초록 (Multilingual Abstract)

The clinical importance of heart failure with preserved ejection fraction (HFpEF) has recently become apparent. HFpEF refers to heart failure (HF) symptoms with normal or near-normal cardiac function on echocardiography. Common clinical features of HFpEF include diastolic dysfunction, reduced compliance, and ventricular hypokinesia. HFpEF differs from the better-known HF with reduced ejection fraction (HFrEF). Despite having a “preserved ejection fraction,” patients with HFpEF have symptoms such as shortness of breath, excessive tiredness, and limited exercise capability. Furthermore, the mortality rate and cumulative survival rate are as severe in HFpEF as they are in HFrEF. While betablockers and renin-angiotensin-aldosterone system modulators can improve the survival rate in HFrEF, no known therapeutic agents show similar effectiveness in HFpEF. Researchers have examined molecular events in the development of HFpEF using small and middle-sized animal models. This review discusses HFpEF with regard to etiology and clinical features and introduces the use of mouse and other animal models of human HFpEF.

참고문헌 (Reference)

1 Bristow, M. R., "beta-adrenergic receptor blockade in chronic heart failure" 101 : 558-569, 2000

2 Campbell, R. T., "What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?" 60 : 2349-2356, 2012

3 Mohammed, S. F., "Variable phenotype in murine transverse aortic constriction" 21 : 188-198, 2012

4 van Heerebeek, L., "Understanding heart failure with preserved ejection fraction: where are we today?" 24 : 227-236, 2016

5 Sancho, J., "The role of the reninangiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects" 53 : 400-405, 1976

6 Unger, T., "The role of the renin-angiotensin-aldosterone system in heart failure" 5 (5): S7-S10, 2004

7 Borlaug, B. A., "The pathophysiology of heart failure with preserved ejection fraction" 11 : 507-, 2014

8 Vallon, V., "The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus" 66 : 255-270, 2015

9 Messina, A. G., "The effect of nitrous oxide on left ventricular pump performance and contractility in patients with coronary artery disease : effect of preoperative ejection fraction" 77 : 954-962, 1993

10 Koruth, J. S., "The clinical use of ivabradine" 70 : 1777-1784, 2017

11 Fukuta, H., "The cardiac cycle and the physiologic basis of left ventricular contraction, ejection, relaxation, and filling" 4 : 1-11, 2008

12 Johnson, M., "The beta-adrenoceptor" 158 : S146-S153, 1998

13 Kong, Y., "Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy" 113 : 2579-2588, 2006

14 Patel, S., "Renin-angiotensin-aldosterone(RAAS) : the ubiquitous system for homeostasis and pathologies" 94 : 317-325, 2017

15 Shearer, F., "Renin-angiotensin-aldosterone system inhibitors in heart failure" 94 : 459-467, 2013

16 Eom, G. H., "Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy" 114 : 1133-1143, 2014

17 Pfeffer, M. A., "Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist(TOPCAT)trial" 131 : 34-42, 2015

18 Nagueh, S. F., "Recommendations for the evaluation of left ventricular diastolic function by echocardiography : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging" 29 : 277-314, 2016

19 Doggrell, S. A., "Rat models of hypertension, cardiac hypertrophy and failure" 39 : 89-105, 1998

20 Hadi, A. M., "Rapid quantification of myocardial fibrosis : a new macrobased automated analysis" 34 : 343-354, 2011

21 Shah, S. J., "Phenomapping for novel classification of heart failure with preserved ejection fraction" 131 : 269-279, 2015

22 Burchfield, J. S., "Pathological ventricular remodeling : mechanisms : part 1 of 2" 128 : 388-400, 2013

23 윤소미, "PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart" 생화학분자생물학회 50 : 1-14, 2018

24 Lavie, C. J., "Obesity and cardiovascular disease : risk factor, paradox, and impact of weight loss" 53 : 1925-1932, 2009

25 Schiattarella, G. G., "Nitrosative stress drives heart failure with preserved ejection fraction" 568 : 351-356, 2019

26 Heinzel, F. R., "Myocardial hypertrophy and its role in heart failure with preserved ejection fraction" 119 : 1233-1242, 2015

27 Ho, C. Y., "Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy" 363 : 552-563, 2010

28 Bombardini, T., "Myocardial contractility in the echo lab : molecular, cellular and pathophysiological basis" 3 : 27-, 2005

29 Valero-Munoz, M., "Murine models of heart failure with preserved ejection fraction: a “fishing expedition”" 2 : 770-789, 2017

30 Horgan, S., "Murine models of diastolic dysfunction and heart failure with preserved ejection fraction" 20 : 984-995, 2014

31 Gerber, Y., "Mortality associated with heart failure after myocardial infarction : a contemporary community perspective" 9 : e002460-, 2016

32 Mohammed, S. F., "Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via “nongenomic effects”" 122 : 370-378, 2010

33 Sam, F., "Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion" 17 : 188-193, 2004

34 Elgendy, I. Y., "Medical therapy for heart failure caused by ischemic heart disease" 124 : 1520-1535, 2019

35 Deacon, R. M., "Measuring motor coordination in mice" e2609-, 2013

36 Kwon, D. H., "MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification" 7 : 10492-, 2016

37 Dunlay, S. M., "Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction" 5 : 720-726, 2012

38 Chen, Y., "Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice : heart failure causes severe lung disease" 59 : 1170-1178, 2012

39 Fox, K., "Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction(BEAUTIFUL) : a randomised, double-blind, placebo-controlled trial" 372 : 807-816, 2008

40 Swedberg, K., "Ivabradine and outcomes in chronic heart failure(SHIFT) : a randomised placebo-controlled study" 376 : 875-885, 2010

41 Redfield, M. M., "Isosorbide mononitrate in heart failure with preserved ejection fraction" 373 : 2314-2324, 2015

42 Van Tassell, B. W., "Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2)" 40 : 626-632, 2017

43 Edvell, A., "Initiation of increased pancreatic islet growth in young normoglycemic mice(Umeå+/?)" 140 : 778-783, 1999

44 Schiattarella, G. G., "Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload" 131 : 1435-1447, 2015

45 Kee, H. J., "Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding" 113 : 51-59, 2006

46 Yoon, S., "Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2" cvy317-cvy317, 2018

47 Roos, K. P., "Hypertrophy and heart failure in mice overexpressing the cardiac sodium-calcium exchanger" 13 : 318-329, 2007

48 Jeong, M. Y., "Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism" 10 : eaao0144-, 2018

49 Bowen, T. S., "High-intensity interval training prevents oxidant-mediated diaphragm muscle weakness in hypertensive mice" 31 : 60-71, 2017

50 Damatto, R. L., "Heart failure-induced skeletal myopathy in spontaneously hypertensive rats" 167 : 698-703, 2013

51 Tibrewala, A., "Heart failure with preserved ejection fraction in women" 15 : 9-18, 2019

52 Redfield, M. M., "Heart failure with preserved ejection fraction" 375 : 1868-1877, 2016

53 Lopatin, Y., "Heart failure with mid-range ejection fraction and how to treat it" 4 : 9-13, 2018

54 Luscher, T. F., "Heart failure subgroups : HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation" 39 : 1-4, 2018

55 Boluyt, M. O., "Heart failure after long-term supravalvular aortic constriction in rats" 18 : 202-212, 2005

56 Clement, K., "Genetics of human obesity" 329 : 608-622, 2006

57 Merino, D., "Experimental modelling of cardiac pressure overload hypertrophy : Modified technique for precise, reproducible, safe and easy aortic arch banding-debanding in mice" 8 : 3167-, 2018

58 Chen, H., "Evidence that the diabetes gene encodes the leptin receptor : identification of a mutation in the leptin receptor gene in db/db mice" 84 : 491-495, 1996

59 Dunlay, S. M., "Epidemiology of heart failure with preserved ejection fraction" 14 : 591-602, 2017

60 Matsumura, Y., "Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B)receptor-deficient rats" 129 : 1060-1062, 2000

61 Zinman, B., "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes" 373 : 2117-2128, 2015

62 Beldhuis, I. E., "Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease" 7 : 25-32, 2019

63 Ostler, J. E., "Effects of insulin resistance on skeletal muscle growth and exercise capacity in type 2 diabetic mouse models" 306 : E592-E605, 2014

64 Wilson, R. M., "Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure" 54 : 583-590, 2009

65 Tanaka, K., "Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction" 7 : 976-985, 2014

66 Marume, K., "Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease—report from the JASPER study" 83 : 357-367, 2019

67 Redfield, M. M., "Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial" 309 : 1268-1277, 2013

68 Komajda, M., "Effect of ivabradine in patients with heart failure with preserved ejection fraction : the EDIFY randomized placebo-controlled trial" 19 : 1495-1503, 2017

69 Borlaug, B. A., "Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction : the INDIEHFpEF randomized clinical trial" 320 : 1764-1773, 2018

70 Reed, A. L., "Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse" 301 : H824-H831, 2011

71 Burlew, B. S., "Diastolic dysfunction in the elderly-the interstitial issue" 13 : 29-38, 2004

72 Borlaug, B. A., "Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum" 123 : 2006-2013, 2011

73 Doi, R., "Development of different phenotypes of hypertensive heart failure : systolic versus diastolic failure in Dahl salt-sensitive rats" 18 : 111-120, 2000

74 Cho, J. H., "Delayed repolarization underlies ventricular arrhythmias in rats with heart failure and preserved ejection fraction" 136 : 2037-2050, 2017

75 Mohammed, S. F., "Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction" 131 : 550-559, 2015

76 Mohammed, S. F., "Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction : a community-based study" 5 : 710-719, 2012

77 Subramanian, S., "Clinical toxicities of histone deacetylase inhibitors" 3 : 2751-2767, 2010

78 Kao, D. P., "Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response" 17 : 925-935, 2015

79 Tsuji, K., "Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study" 19 : 1258-1269, 2017

80 Zhang, L., "Changes of brain activity in the aged SAMP mouse" 8 : 81-88, 2007

81 Eom, G. H., "Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart" 123 : 2392-2403, 2011

82 Lam, C. S., "Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota" 115 : 1982-1990, 2007

83 Hulsmans, M., "Cardiac macrophages promote diastolic dysfunction" 215 : 423-440, 2018

84 Pfeffer, J. M., "Cardiac function and morphology with aging in the spontaneously hypertensive rat" 237 : H461-H468, 1979

85 Cleland, J. G. F., "Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction : an individual patient-level analysis of doubleblind randomized trials" 39 : 26-35, 2018

86 Mottram, P. M., "Assessment of diastolic function : what the general cardiologist needs to know" 91 : 681-695, 2005

87 Grobe, J. L., "Angiotensinergic signaling in the brain mediates metabolic effects of deoxycorticosterone(DOCA)-salt in C57 mice" 57 : 600-607, 2011

88 McMurray, J. J., "Angiotensin-neprilysin inhibition versus enalapril in heart failure" 371 : 993-1004, 2014

89 Solomon, S. D., "Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction : rationale and design of the PARAGON-HF trial" 5 : 471-482, 2017

90 Bull, M., "Alternative splicing of titin restores diastolic function in an HFpEFlike genetic murine model TtnΔIAjxn" 119 : 764-772, 2016

91 Zannad, F., "Aldosterone and heart failure" 16 (16): 98-102, 1995

92 Beetz, N., "Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload" 101 : 145-155, 2016

93 McMurray, J. J. V., "A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction(DAPA-HF)" 21 : 665-675, 2019

94 Yancy, C. W., "2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America" 136 : e137-e161, 2017

95 Ponikowski, P., "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC" 18 : 891-975, 2016